EYPT
EyePoint Pharmaceuticals, Inc.
There isn't enough reported data to score EYPT yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
EYPT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
EYPT's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
EYPT PE Valuation
EYPT has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
EYPT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Moderate | |
| Low |
Analysts expect EYPT's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
EYPT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.97 | -$0.97 |
| Q2 2026 | -$3.75 | -$1.06 |
| Q1 2026 | -$3.51 | -$1.09 |
| Q4 2025 | -$3.17 | -$0.85 |
| Q3 2025 | -$3.00 | -$1.01 |
| Q2 2025 | -$2.69 | -$0.91 |
| Q1 2025 | -$2.42 | -$0.61 |
| Q4 2024 | -$2.32 | -$0.50 |
EYPT is still losing money, but less than at its worst: $3.97 per share over the past year, against $5.60 at its worst in late 2019.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over EYPT on earnings quality, reporting a profit while its opponent remains loss making.
EYPT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $756K | -22% |
| Q2 2026 | $507K | -90% |
| Q1 2026 | $696K | -97% |
| Q4 2025 | $620K | -95% |
| Q3 2025 | $966K | -91% |
| Q2 2025 | $5.3M | -44% |
| Q1 2025 | $24.5M | +109% |
| Q4 2024 | $11.6M | -17% |
EYPT's revenue has slid since its 2025 peak: $756,000 last quarter, down 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -12814% | -6394 points |
| Q2 2026 | -19207% | -18040 points |
| Q1 2026 | -12532% | -12333 points |
| Q4 2025 | -11346% | -10956 points |
| Q3 2025 | -6421% | -6110 points |
| Q2 2025 | -1167% | -802 points |
| Q1 2025 | -200% | +86 points |
| Q4 2024 | -390% | -274 points |
EYPT's operating margin was −12814% last quarter, down 6394 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over EYPT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over EYPT on profitability, with a higher operating margin.
EYPT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$88M | -$27.9M |
| Q2 2026 | -$63.5M | +$261K |
| Q1 2026 | -$81.5M | -$28.2M |
| Q4 2025 | -$66M | -$29.8M |
| Q3 2025 | -$60.2M | -$19.6M |
| Q2 2025 | -$63.8M | -$42.7M |
| Q1 2025 | -$53.4M | -$21M |
| Q4 2024 | -$36.2M | -$12.2M |
EYPT has burned cash in almost every quarter: −$299M over the past year, against −$214M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over EYPT on cash generation, producing positive trailing cash flow while its opponent burns cash.
EYPT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +28% | +15.3M shares |
| 1 year | +86% | +32.2M shares |
| 3 years | +143% | +41M shares |
EYPT has 70M diluted shares, up 86% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over EYPT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
EYPT Net Leverage
EYPT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
EYPT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.9 | Oversold |
| Stochastic | 0.1 | Oversold |
EYPT's weekly RSI is 23 (oversold) and its Stochastic is 0 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
EYPT PE vs Healthcare Sector
EYPT has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
EYPT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.84 | 83% below |
| 20 week MA | $6.61 | 95% below |
| 50 week MA | $11.3 | 97% below |
| 100 week MA | $10.3 | 97% below |
| 200 week MA | $10.8 | 97% below |
EYPT is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over EYPT on trend strength, trading above more of its moving averages.
EYPT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.0 | $4.99 | -67% |
| 2021 | $4.99 | $13.6 | +172% |
| 2022 | $13.6 | $2.89 | -79% |
| 2023 | $2.89 | $23.1 | +700% |
| 2024 | $23.1 | $7.20 | -69% |
| 2025 | $7.20 | $18.3 | +154% |
| 2026 YTD | $18.3 | $0.32 | -98% |
EYPT's yearly returns have swung widely, from +700% in 2023 to −79% in 2022. It's down 98% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over EYPT on returns for 2026, with the stronger performance.